300,648 Shares in Tango Therapeutics, Inc. $TNGX Purchased by DV Trading LLC

DV Trading LLC acquired a new position in Tango Therapeutics, Inc. (NASDAQ:TNGX) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 300,648 shares of the company’s stock, valued at approximately $6,290,000. Tango Therapeutics comprises about 0.1% of DV Trading LLC’s holdings, making the stock its 8th largest holding.

Other large investors also recently bought and sold shares of the company. Invesco Ltd. lifted its position in shares of Tango Therapeutics by 138.8% in the first quarter. Invesco Ltd. now owns 70,517 shares of the company’s stock valued at $97,000 after acquiring an additional 40,983 shares in the last quarter. AQR Capital Management LLC acquired a new stake in shares of Tango Therapeutics in the first quarter worth approximately $195,000. Dynamic Technology Lab Private Ltd increased its position in shares of Tango Therapeutics by 139.7% during the first quarter. Dynamic Technology Lab Private Ltd now owns 25,801 shares of the company’s stock worth $35,000 after purchasing an additional 15,037 shares in the last quarter. Woodline Partners LP increased its position in shares of Tango Therapeutics by 28.3% during the first quarter. Woodline Partners LP now owns 506,188 shares of the company’s stock worth $693,000 after purchasing an additional 111,791 shares in the last quarter. Finally, Jane Street Group LLC increased its position in shares of Tango Therapeutics by 270.6% during the first quarter. Jane Street Group LLC now owns 352,897 shares of the company’s stock worth $483,000 after purchasing an additional 257,668 shares in the last quarter. 78.99% of the stock is currently owned by hedge funds and other institutional investors.

Tango Therapeutics Price Performance

TNGX stock opened at $27.18 on Friday. Tango Therapeutics, Inc. has a 1 year low of $5.77 and a 1 year high of $34.39. The firm has a market capitalization of $3.93 billion, a PE ratio of -32.75 and a beta of 1.12. The business has a 50 day simple moving average of $27.68 and a 200-day simple moving average of $21.18.

Tango Therapeutics (NASDAQ:TNGX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.32) EPS for the quarter, hitting analysts’ consensus estimates of ($0.32). On average, equities research analysts expect that Tango Therapeutics, Inc. will post -1.27 EPS for the current year.

Insider Transactions at Tango Therapeutics

In other Tango Therapeutics news, insider Adam Crystal sold 27,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $29.59, for a total value of $798,930.00. Following the completion of the sale, the insider directly owned 115,743 shares of the company’s stock, valued at $3,424,835.37. This trade represents a 18.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 6.50% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of research analysts have weighed in on TNGX shares. B. Riley Financial restated a “buy” rating on shares of Tango Therapeutics in a report on Monday, June 8th. Jefferies Financial Group raised shares of Tango Therapeutics from a “hold” rating to a “buy” rating and upped their target price for the stock from $27.00 to $60.00 in a report on Thursday, June 25th. UBS Group set a $55.00 target price on shares of Tango Therapeutics in a report on Thursday, May 14th. Canaccord Genuity Group increased their target price on shares of Tango Therapeutics from $42.00 to $46.00 and gave the company a “buy” rating in a research report on Monday, June 29th. Finally, Wedbush raised their price target on shares of Tango Therapeutics from $19.00 to $33.00 and gave the stock an “outperform” rating in a research note on Thursday, May 14th. Thirteen equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Tango Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $42.15.

About Tango Therapeutics

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.